Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in District of Columbia: - Kaiser Permanente-Capitol Hill Medical Center — Washington D.C., District of Columbia
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in District of Columbia: - Medstar Georgetown University Hospital — Washington D.C., District of Columbia
- Washington Cancer Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in District of Columbia: - The George Washington Medical facility Associates — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to lea…
Sponsor: Ana C Garrido-Castro, MD
NCT ID: NCT06533826
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Sponsor: Normunity AccelCo, Inc.
NCT ID: NCT07182149
Sites in District of Columbia: - Normunity Investigational Site — Washington D.C., District of Columbia
Recruiting Academic/Other
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Sponsor: Abramson Cancer Center at Penn Medicine
NCT ID: NCT06551116
Sites in District of Columbia: - Georgetown University - Lombardi CCC — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The goal of this study is to test bundled familial cancer risk assessment + multicancer (colorectal + breast) vs. single (breast) cancer navigation, using a wait list control for colorectal cancer screening referral and navigation. Among t…
Sponsor: Georgetown University
NCT ID: NCT07228000
Sites in District of Columbia: - Georgetown University — Washington D.C., District of Columbia
Recruiting Academic/Other
Traditional clinical trials in patients with breast cancer leptomeningeal disease (LMD) are challenging as patients often have a rapidly progressive course and prognosis is poor, making meeting standard eligibility difficult. Furthermore, …
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06638294
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia